The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease

被引：2
|
作者：
Lincoff, A. Michael [1 ]
Ryan, Donna H. [2 ]
机构：
[1] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Cardiovasc Med, Cleveland, OH USA
[2] Pennington Biomed Res Ctr, Baton Rouge, LA USA
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2024年 / 10卷 / 02期
关键词：
D O I：
10.1093/ehjcvp/pvad097
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [21] SEMAGLUTIDE IMPROVES LIVER ENZYMES AND FATTY LIVER INDEX IN PATIENTS WITH OBESITY AND CARDIOVASCULAR DISEASE - RESULTS FROM THE SELECT TRIAL
    Meyhoefer, Sebastian
    Cariou, Bertrand
    Cercato, Cintia
    Colhoun, Helen
    Deanfield, John
    Kjaer, Mette Skalshoi
    Jeppesen, Ole
    Lincoff, A. Michael
    Lingvay, Ildiko
    Newsome, Phillip
    Nicholls, Stephen
    Pelaez, Maria De Los Angeles Quiroga
    Santini, Ferruccio
    Sanyal, Arun
    Kahn, Steven
    HEPATOLOGY, 2024, 80 : S457 - S459
  • [22] Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide
    Lan, Nick S. R.
    Ali, Umar S.
    Larbalestier, Robert
    Dwivedi, Girish
    Fegan, P. Gerry
    OBESITY RESEARCH & CLINICAL PRACTICE, 2024, 18 (01) : 76 - 78
  • [23] A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes
    Carney, Ellen F.
    NATURE REVIEWS NEPHROLOGY, 2024, 20 (08) : 493 - 493
  • [24] Is semaglutide as effective at reducing major cardiovascular events in the presence of impaired kidney function in people with overweight or obesity? A prespecified analysis from the SELECT trial
    Colhoun, H. M.
    Kahn, S. E.
    Brown, P. M.
    Olesen, E. T. B.
    Bravo, R.
    Deanfield, J.
    Goudev, A.
    Latkovskis, G.
    Lehrke, M.
    Lincoff, A. M.
    Rathor, N.
    Wu, C. -C.
    Lingvay, I.
    DIABETOLOGIA, 2024, 67 : S80 - S81
  • [25] Eligibility and Preventable CVD Events in US Adults with Cardiovascular Disease and Overweight or Obesity: Projections from the SELECT Trial
    Yan, Hongmei
    Karthikeyan, Hridhay
    Fan, Wenjun
    Yang, Qin
    Wong, Nathan
    CIRCULATION, 2024, 150
  • [26] STARTing a new path in cardiovascular prevention: Lessons from SELECT and real-world evidence on Semaglutide in obesity-driven risk
    Ando, Giuseppe
    Cavolina, Giulia
    Villari, Alessio
    Sabouret, Pierre
    Musumeci, Giuseppe
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2025, 425
  • [27] Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial
    Nicholls, Stephen J.
    Nelson, Adam J.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (04) : 343 - 348
  • [28] Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial
    Stephen J. Nicholls
    Adam J. Nelson
    American Journal of Cardiovascular Drugs, 2019, 19 : 343 - 348
  • [29] Secondary prevention of cardiovascular disease and diabetes: still suboptimal in patients with myocardial infarction
    Chin, BSP
    Kharim, S
    Ghaffar, A
    Rehman, A
    Lip, GYH
    JOURNAL OF INTERNAL MEDICINE, 2001, 250 (02) : 180 - 181
  • [30] Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)
    Pagidipati, Neha J.
    Navar, Ann Marie
    Pieper, Karen S.
    Green, Jennifer B.
    Bethel, M. Angelyn
    Armstrong, Paul W.
    Josse, Robert G.
    McGuire, Darren K.
    Lokhnygina, Yuliya
    Cornel, Jan H.
    Halvorsen, Sigrun
    Strandberg, Timo E.
    Delibasi, Tuncay
    Holman, Rury R.
    Peterson, Eric D.
    CIRCULATION, 2017, 136 (13) : 1193 - +
12345